UID:
almahu_9949982906602882
Format:
1 online resource (290 pages)
Edition:
First edition.
ISBN:
9780443190926
,
0443190925
Content:
This book, edited by Fabian Sanchis-Gomar and Amer Harky, explores the various consequences of COVID-19 on the cardiovascular and systemic health of individuals. It provides a comprehensive analysis of immediate, intermediate, and long-term complications that arise from SARS-CoV-2 infection. The book discusses the direct myocardial and pericardial injuries caused by the virus, the inflammatory response, and the implications of the cytokine storm. It also examines the effects of COVID-19 on pulmonary vasculature, comorbidities, and the prognostic role of biomarkers. Further topics include the impact on cardiology and surgery services, cardiac arrhythmias, heart failure, and autoimmune diseases. The book is intended for medical professionals, researchers, and practitioners interested in the systemic effects of COVID-19 and aims to enhance understanding and management of these conditions.
Note:
Front Cover -- COVID-19's Consequences on the Cardiovascular System -- Copyright Page -- Contents -- List of contributors -- Foreword -- Introduction -- Introduction -- 1 The pathophysiology of COVID-19 and the cardiovascular system -- Introduction -- Direct myocardial and pericardial injury by SARS-CoV-2 -- Cardiovascular implications of SARS-CoV-2 effect on the renin-angiotensin system -- The inflammatory response to SARS-CoV-2 infection -- Cardiovascular implications of the cytokine storm -- Effect of cytokine storm on systemic vasculature -- Hypercoagulable state -- Disseminated intravascular coagulation -- The effect of SARS-CoV-2 on the pulmonary vasculature -- Conclusion -- References -- 2 Cardiovascular comorbidities and COVID-19 outcomes -- Introduction -- Risk of severity outcomes and mortality in COVID-19: scientific evidence -- Hypertension -- Coronary heart disease -- Heart failure -- Atrial fibrillation -- Possible mechanisms involved -- Concluding remarks -- References -- 3 Prognostic role of troponins and other cardiac-related biomarkers in COVID-19 -- What are biomarkers? -- The importance of cardiac biomarkers -- Role of troponins in COVID-19 -- Significance of raised cardiac troponins (cTroponins) in COVID-19 -- Robust prognostic marker or misdirect/red herring? -- Role of CK-Mb in COVID-19 -- Other cardiac biomarkers -- Myoglobin-biochemistry -- Pathophysiology of the rise of myoglobin -- Myoglobin as a mortality predictor -- Drawbacks -- Role of nonspecific markers in COVID-19 -- Role of C-reactive protein -- Role of interleukin-6 -- Role of lactate dehydrogenase -- Summary -- References -- 4 Cardiovascular medications and its relations with COVID-19 survival -- Introduction -- Drug categories -- Beta-adrenoceptor blockers -- Aspirin -- Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers -- Anticoagulants.
,
COVID-19 and prothrombotic parameters -- Vitamin K antagonist/warfarin -- Heparins -- Direct-acting oral anticoagulants -- Anticoagulant medication and COVID-19 survival -- Calcium channel blockers -- Diuretics -- Antiarrhythmics -- Class I -- Class II -- Class III -- Class IV -- Class V (miscellaneous) -- Statins -- Indications for statin usage -- Mechanism of action -- Side effects, contraindications, and interactions -- Statin usage in COVID-19 -- Proposed mechanism of action of statins alongside COVID-19 pathophysiology -- Statin use preceding COVID-19 infection -- Statin use during COVID-19 infection -- Statin use and COVID-19: conclusion -- Conclusion -- References -- 5 Imaging in Covid-19 -- Chest radiographs -- Computerized tomography of the chest -- Lung ultrasound -- Magnetic resonance imaging -- Covid-19 imaging in pregnancy -- Covid-19 imaging in children and neonates -- Imaging of cardiovascular complications of Covid-19 -- Myocarditis -- Thrombotic events -- Conclusions -- References -- 6 Long-term impact of COVID-19 on the cardiovascular system -- Introduction -- Definitions of long-COVID -- Epidemiology of long-COVID -- Prevalence and predictors of long-COVID: increased risk of cardiovascular disease after COVID-19 infection -- Potential long-term cardiovascular effects of COVID-19 -- The effect of long-COVID on the cardiovascular system -- Heart muscle -- Blood vessels -- Autonomic nervous system dysfunction -- Inflammation and plaque vulnerability -- Additional risk factors for developing severe and long-COVID cardiovascular disease complications -- Symptoms and pathophysiological mechanisms in long-COVID -- Diagnosis, management, and treatment of cardiovascular effects and complications -- Cardiovascular system biomarkers to detect and manage long-COVID.
,
Treatment of cardiovascular disorders/syndromes/manifestations associated with long-COVID -- The RECOVER Initiative at Stanford Medicine: an NIH-funded long-COVID study -- Concluding remarks and future directions -- References -- 7 Pericardial and myocardial manifestations of COVID-19 -- Introduction -- Pathophysiology -- Myocarditis -- Symptoms -- Investigations -- Biomarkers -- Electrocardiogram -- Echocardiogram -- Computer tomography -- Cardiac magnetic resonance imaging -- Endomyocardial biopsy -- Outcomes of COVID myocarditis -- Treatment strategies -- Pericarditis and myopericarditis -- Pericarditis -- Diagnostic criteria -- Investigations -- Symptoms and biomarkers -- Investigations -- Electrocardiogram -- Echocardiogram -- Myopericarditis -- Investigations -- Outcomes of pericarditis and myopericarditis -- Treatment of patients with pericarditis and myopericarditis -- Conclusion -- COVID vaccine -- Myocarditis, myopericarditis, and pericarditis as a result of vaccination against COVID-19 -- Factors which may contribute to COVID-19 vaccine side effects -- Gender -- Age -- Vaccine manufacturer -- Second vaccination dose -- Conclusion -- References -- 8 The thromboembolic effect of COVID-19 -- Introduction -- Epidemiology of venous thromboembolism in COVID-19 -- Epidemiology of venous thromboembolism during acute SARS-CoV-2 infection -- Epidemiology of venous thromboembolism after recovering from an acute SARS-CoV-2 infection -- Predisposing factors of venous thromboembolism in COVID-19 -- Prognosis of venous thromboembolism in COVID-19 -- In situ pulmonary thrombosis -- Conclusions -- References -- 9 COVID-19 and platelets: an enigmatic relationship -- Introduction -- Platelet count in COVID-19 -- Platelet volume in COVID-19 -- Immature platelets in COVID-19 -- Biological basis of platelet abnormalities in COVID-19.
,
Antiplatelet treatment in COVID-19 -- Conclusions -- References -- 10 Cardiology service and COVID-19: the international impact -- Introduction -- The impact in Africa -- The impact in Europe -- Outpatient -- Inpatient -- Cardiac investigations -- Cardiac procedures -- Conclusion -- COVID-19 and its impact on cardiology services in Asia -- General study -- Cardiac rehabilitation (worldwide) -- Thoracic surgery -- Cardiology testing in a South Asian low- and middle-income countries -- COVID-19 pandemic impact on the US Cardiology Service -- Outpatient cardiology service in the United States -- Benefits of interactive telehealth -- Challenges that interactive telehealth faced -- HIPAA and temporary waiver of Medicare restrictions -- Inpatient cardiology services and reimbursement structure for ITH -- References -- 11 Cardiovascular surgery services during COVID-19 pandemic -- Introduction -- Impact of COVID-19 on cardiovascular surgery services -- Impact of the COVID-19 pandemic on cardiovascular surgery in United Kingdom -- Global impact of the COVID-19 pandemic on cardiovascular surgery -- Responses and adaptations of cardiovascular surgery services to COVID-19 -- Europe -- London, England -- Lombardy, Italy -- North and South America -- New York City, United States -- Brazil -- Africa -- South Africa -- Asia -- Hong Kong and Mainland China -- India -- Australasia -- Australia and New Zealand -- Innovation in cardiovascular surgery services during the pandemic -- Telemedicine -- Benefits and difficulties associated with telemedicine -- Future perspectives -- Conclusion -- References -- 12 Cardiac arrhythmia and sudden death in relation to COVID-19 -- Introduction -- Pathophysiology of arrhythmias in previous coronavirus outbreaks -- Pathophysiology of arrhythmias in cases of influenza virus -- Pathophysiology of arrhythmias in SARS-CoV-2.
,
Electrolyte abnormalities and cardiac arrhythmias -- Hyponatremia -- Hypokalemia -- Inflammatory markers and their mediation of cardiac arrhythmias -- Hypoxia-induced cardiac arrhythmias -- Drug effect for COVID-19 management and interactions with other medications -- Structural heart disease -- Pulmonary embolism and its associated arrhythmias -- Adrenergic stress leading to arrhythmias -- Sudden death in COVID-19 -- Mechanism of sudden cardiac death in COVID-19 -- Management -- References -- 13 Heart failure and acute coronary syndrome with COVID-19 -- Heart failure and COVID-19 -- Background of heart failure -- Heart failure epidemiology -- Prior to COVID-19 -- Impact of COVID-19 on heart failure epidemiology -- Heart failure physiology in COVID -- Ischemia -- Myocarditis -- Left ventricular dysfunction -- Right heart failure -- Heart failure medications in COVID-19 -- Suggested COVID-19 medications and impact on heart failure -- Myocardial injury biomarkers in heart failure and COVID-19 -- Signs and symptoms of heart failure in COVID-19 -- Investigations -- Bedside testing -- Laboratory tests -- Imaging -- Management -- Future primary prevention measure for heart failure -- Acute coronary syndrome (ACS) and COVID-19 -- Introduction to ACS in COVID-19-positive patients -- Epidemiology of ACS during the COVID-19 pandemic -- Pathophysiology of ACS in COVID-19 positive patients -- Plaque rupture (Type 1 AMI) -- Hypercoagulable state -- Type 2 AMI -- Endothelial dysfunction (ED) -- Presentation of ACS in COVID-19-positive patients -- Diagnosis of ACS in COVID-19-positive patients -- Differential diagnosis -- Diagnostic markers -- Troponin I -- d-dimer -- BNP/NT-proBNP -- Noninvasive diagnostic imaging -- Echocardiography -- Cardiac CT (CCT)/cardiac MRI (CMR) -- CT chest/CT pulmonary angiogram/coronary CT angiogram.
,
Management of ACS during the COVID-19 pandemic.
Additional Edition:
ISBN 9780443190919
Additional Edition:
ISBN 0443190917
Language:
English
Bookmarklink
